The findings by Levine's group [8] and our group [18], suggesting that both the MDM2 promoter SNP's 309 and 285 may have an effect on cancer risk, implies the importance of fine tuning of MDM2 levels with respect to carcinogenesis, and also indicate that other MDM2 promoter variants could potentially be of importance. Here, MDM2 is linked to cancer.